Byoung Chul Cho

TL;DR: The dual inhibition of EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than gefithinib alone as a second-line treatment of advanced NSCLC and combined treatment did not increase EGFR inhibition-related adverse events with manageable toxicities.

TL;DR: A Smith-Waterman algorithm-based mutation hotspot discovery method, MutClustSW, is developed to identify mutation hotspots of either single or clustered amino acid residues and shows that hotspot mutations have higher mutation allele frequency than non-hotspots, and the hotspot information can be used to prioritize the cancer drivers.

TL;DR: Treatment benefit with durvalumab versus placebo was maintained regardless of the occurrence of pneumonitis, which predominantly occurred with low-grade severity as previously reported, and these findings suggest that low- grade pneum onitis should not deter use of durvaluab.

TL;DR: ERCC1 and RRM1 mRNA expression-based chemotherapy did not improve clinical outcomes in advanced NSCLC and was prematurely terminated after the futility analysis of 43 progression-free survival (PFS) events.

TL;DR: It is hypothesize that combination therapy will prolong PFS and OS compared with placebo in this setting, and concomitant blockade of PD-L1/PD-1 and TIGIT pathways demonstrated prolonged survival over the respective single-agents.